Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical ...
A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.
US-supported international HIV research, particularly that conducted in African countries, has direct benefits to Americans. Cuts to that research may undermine those benefits.
The World Health Organization (WHO) says it has supported nine countries to begin rolling out lenacapavir, a long-acting HIV prevention medicine, targeting people at high risk of infection across ...
HIV spreads in the human body by targeting and infecting T cells, the critical white blood cells of our immune system. PrEP ...
At the 69th session of the Commission on Narcotic Drugs (CND), UNAIDS, the United Nations Development Programme (UNDP) and the International Network of People who Use Drugs (INPUD), together with ...
– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...
Kenya's health authorities have begun administering lenacapavir, a long-acting HIV prevention drug delivered by injection ...
Mr Ghebreyesus said a new medicine approved in 2025 for HIV prevention, Lenacapavir, represents the most significant development in combating HIV since the first antiretroviral treatments were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results